WOONSOCKET, R.I., May 4, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Shawn Guertin will participate in fireside chats with investors at the 2023 Bank of America Securities Health Care Conference on May 10, 2023, at approximately 8:40 a.m. PT, and at Bernstein's 39th Annual Strategic Decisions Conference on May 31, 2023, at 9 a.m. ET.
An audio webcast of each event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where they will be archived for a period of one year.
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Last Trade: | US$82.26 |
Daily Change: | -0.78 -0.94 |
Daily Volume: | 1,928,934 |
Market Cap: | US$104.470B |
October 15, 2025 July 10, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load